SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

J&J to Acquire Ollin Biosciences for $2.2 Billion Upfront

Johnson & Johnson is acquiring Ollin Biosciences to gain OLN324, a Phase three bispecific antibody for retinal diseases. The deal includes $2.2 billion upfront.

JNJ

Story updates

01:56:48 PM UTC
SquawkNews
Blackstone Life Sciences is committing $750 million to fully fund Phase three development of OLN324, the retinal drug J&J is acquiring through its Ollin Biosciences purchase. In exchange, Blackstone will receive regulatory and sales milestone payments plus single-digit royalties. The arrangement sh…

Johnson & Johnson is acquiring Ollin Biosciences for $2.2 billion upfront to gain OLN324, a Phase three bispecific antibody for retinal diseases. The deal reflects J&J's push to expand in ophthalmology, where it already has a presence. OLN324 targets both vascular endothelial growth factor and angi…

Related stories